Evidence map›Paper›PMID 37210697›Full record

ArticleOphthalmology and therapy2023

Development of Novel Patient-Reported Outcome (PRO) and Observer-Reported Outcome (ObsRO) Instruments in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA): ViSIO-PRO and ViSIO-ObsRO.

Isabelle Audo, Francesco Patalano, Christel Naujoks, Claudio Spera, M Dominik Fischer, Jane Green, Christine Kay, Todd Durham, Nicola Williamson, Helena Bradley and 3 more

Open access · goldAbstract read
In one paragraph

Article in Ophthalmology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 6 countries.

Isabelle AudoSorbonne Université, INSERM, CNRS, Institut de La Vision, CHNO Des Quinze-Vingts, National Rare Disease Center REFERET and INSERM-DGOS CIC 1423, 75012, Paris, France.
Francesco PatalanoNovartis Pharma AG, Basel, Switzerland.ORCID http://orcid.org/0000-0001-7015-6084
Christel NaujoksNovartis Pharma AG, Basel, Switzerland.ORCID http://orcid.org/0000-0002-3799-6521
Claudio SperaNovartis Pharma AG, Basel, Switzerland.
M Dominik FischerDepartment of Clinical Neurosciences, University of Oxford, Oxford, UK.
Jane GreenDiscipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, Craig L Dobbin Genetics Research Centre, St. John's, Canada.
Christine KayVitreoretinal Associates, Gainesville, FL, USA.
Todd DurhamFoundation Fighting Blindness, Columbia, MD, USA.ORCID http://orcid.org/0000-0002-0363-0329
Nicola WilliamsonAdelphi Values Ltd, Bollington, Cheshire, UK.
Helena BradleyAdelphi Values Ltd, Bollington, Cheshire, UK. helena.bradley@adelphivalues.com.ORCID http://orcid.org/0000-0002-7077-2183
Melissa BarclayAdelphi Values Ltd, Bollington, Cheshire, UK.
Kieran BoparaiAdelphi Values Ltd, Bollington, Cheshire, UK.
Judit BanhaziNovartis Pharma AG, Basel, Switzerland.
Adelphi Group (United Kingdom) · GBNovartis (Switzerland) · CHCentre National de la Recherche Scientifique · FRFoundation Fighting Blindness · USMemorial University of Newfoundland · CARetina Vitreous Associates of Florida · USUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRetinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) are rare inherited retinal degenerative disorders resulting in visual impairments and impacts on patients' vision-dependent activities of daily living (ADL), mobility and distal health-related quality of life (HRQoL). This study aimed to conduct qualitative research to understand the patient experience of RP/LCA across genotypes and inform development of patient- and observer-reported outcome (PRO/ObsRO) instruments in RP/LCA.

methodsResearch activities included a qualitative literature review and review of existing visual function PRO instruments in RLBP1 RP, and concept elicitation (CE) and cognitive debriefing (CD) interviews of existing PRO instruments with patients with RLBP1 RP, expert clinicians, and payers. In wider RP/LCA, a social media listening (SML) study and a qualitative literature review was conducted, while psychometric evaluation of a PRO instrument in LCA was performed. Input from expert clinicians was sought at key stages.

resultsFindings from the qualitative literature reviews identified a range of visual function symptoms which had significant impacts on patients' vision-related ADL and distal HRQoL. Patient interviews identified additional visual function symptoms and impacts not previously reported in published literature. These sources informed development and refinement of a conceptual model displaying the patient experience of RP/LCA. Review of existing visual function PRO instruments, and CD interviews evaluating their content validity, confirmed that no existing instrument provides a comprehensive assessment of all concepts relevant to patients with RP/LCA. This highlighted the need for development of the Visual Symptom and Impact Outcomes PRO and ObsRO instruments to adequately assess the patient experience of RP/LCA.

conclusionsResults informed and supported development of the instruments to assess visual functioning symptoms and vision-dependent ADL, mobility and distal HRQoL in RP/LCA, in accordance with regulatory standards. Next steps to further support use in RP/LCA clinical trials/practice includes content and psychometric validation of the instruments in this population.

Indexed as

Clinical outcome assessmentHealth-related quality of lifeInherited retinal degenerationsLeber congenital amaurosisObserver-reported outcomePatient-reported outcomeQualitative literature reviewRetinitis pigmentosaVisual function symptoms

Identifiers

PMID37210697
PMCPMC10287847
OpenAlexW4377192892

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.